CMS grants Delcath ‘NTAP,’ status for HEPZATO KIT

Delcath Systems announced that the Centers for Medicare & Medicaid Services CMS has granted New Technology Add-on Payment or NTAP, status for its HEPZATO KIT, melphalan/Hepatic Delivery System. This approval will be effective for the fiscal year starting October 1. The NTAP designation under the CMS Inpatient Prospective Payment System, IPPS, is designed to support the adoption of innovative medical technologies that provide substantial clinical improvement over existing treatments. HEPZATO KIT is used primarily in the outpatient setting, however there are instances where it is used in the inpatient setting. This additional payment will help to cover the costs associated with the HEPZATO KIT for eligible Medicare inpatients, ensuring that more patients can benefit from this advanced liver-directed therapy. “The NTAP approval for HEPZATO KIT is a significant milestone that underscores the clinical value of our therapy. This will facilitate broader access to HEPZATO KIT for eligible patients and support the oncology community in delivering this important treatment,” stated Gerard Michel, CEO of Delcath Systems….The HEPZATO KIT is indicated for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma.